84 related articles for article (PubMed ID: 12183060)
21. Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways.
Schnaper HW; Barnathan ES; Mazar A; Maheshwari S; Ellis S; Cortez SL; Baricos WH; Kleinman HK
J Cell Physiol; 1995 Oct; 165(1):107-18. PubMed ID: 7559792
[TBL] [Abstract][Full Text] [Related]
22. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
McGowen R; Biliran H; Sager R; Sheng S
Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
[TBL] [Abstract][Full Text] [Related]
23. Concomitant secretion of prourokinase and of a plasminogen activator-specific inhibitor by cultured human monocytes-macrophages.
Vassalli JD; Dayer JM; Wohlwend A; Belin D
J Exp Med; 1984 Jun; 159(6):1653-68. PubMed ID: 6374011
[TBL] [Abstract][Full Text] [Related]
24. Urokinase-type plasminogen activator stimulation of monocyte matrix metalloproteinase-1 production is mediated by plasmin-dependent signaling through annexin A2 and inhibited by inactive plasmin.
Zhang Y; Zhou ZH; Bugge TH; Wahl LM
J Immunol; 2007 Sep; 179(5):3297-304. PubMed ID: 17709546
[TBL] [Abstract][Full Text] [Related]
25. Urokinase plasminogen activator upregulates paraoxonase 2 expression in macrophages via an NADPH oxidase-dependent mechanism.
Fuhrman B; Khateeb J; Shiner M; Nitzan O; Karry R; Volkova N; Aviram M
Arterioscler Thromb Vasc Biol; 2008 Jul; 28(7):1361-7. PubMed ID: 18436804
[TBL] [Abstract][Full Text] [Related]
26. THP-1 macrophage membrane-bound plasmin activity is up-regulated by transforming growth factor-beta 1 via increased expression of urokinase and the urokinase receptor.
Falcone DJ; McCaffrey TA; Mathew J; McAdam K; Borth W
J Cell Physiol; 1995 Aug; 164(2):334-43. PubMed ID: 7622580
[TBL] [Abstract][Full Text] [Related]
27. Receptor-bound uPA is reversibly protected from inhibition by low molecular weight inhibitors.
Dyer KD; Linz-Mcgillem LA; Alliegro MA; Alliegro MC
Cell Biol Int; 2002; 26(4):327-35. PubMed ID: 11991662
[TBL] [Abstract][Full Text] [Related]
28. Urokinase-type plasminogen activator in inflammatory cell recruitment and host defense against Pneumocystis carinii in mice.
Beck JM; Preston AM; Gyetko MR
Infect Immun; 1999 Feb; 67(2):879-84. PubMed ID: 9916103
[TBL] [Abstract][Full Text] [Related]
29. Alveolar macrophage urokinase receptors localize enzyme activity to the cell surface.
Chapman HA; Bertozzi P; Sailor LZ; Nusrat AR
Am J Physiol; 1990 Dec; 259(6 Pt 1):L432-8. PubMed ID: 2175557
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor.
Towle MJ; Lee A; Maduakor EC; Schwartz CE; Bridges AJ; Littlefield BA
Cancer Res; 1993 Jun; 53(11):2553-9. PubMed ID: 8495419
[TBL] [Abstract][Full Text] [Related]
31. IFN-gamma, tumor necrosis factor-alpha, and urokinase regulate the expression of urokinase receptors on human monocytes.
Kirchheimer JC; Nong YH; Remold HG
J Immunol; 1988 Dec; 141(12):4229-34. PubMed ID: 2848891
[TBL] [Abstract][Full Text] [Related]
32. Regulated localization confers multiple functions on the protease urokinase plasminogen activator.
Wells JM; Strickland S
J Cell Physiol; 1997 May; 171(2):217-25. PubMed ID: 9130470
[TBL] [Abstract][Full Text] [Related]
33. Reduced monocyte adhesion to aortae of diabetic plasminogen activator inhibitor-1 knockout mice.
Zhao R; Le K; Moghadasian MH; Shen GX
Inflamm Res; 2017 Sep; 66(9):783-792. PubMed ID: 28550522
[TBL] [Abstract][Full Text] [Related]
34. 2-Amidino analogs of glycine-amiloride conjugates: inhibitors of urokinase-type plasminogen activator.
Massey AP; Harley WR; Pasupuleti N; Gorin FA; Nantz MH
Bioorg Med Chem Lett; 2012 Apr; 22(7):2635-9. PubMed ID: 22366654
[TBL] [Abstract][Full Text] [Related]
35. Urokinase-type plasminogen activator plays essential roles in macrophage chemotaxis and skeletal muscle regeneration.
Bryer SC; Fantuzzi G; Van Rooijen N; Koh TJ
J Immunol; 2008 Jan; 180(2):1179-88. PubMed ID: 18178858
[TBL] [Abstract][Full Text] [Related]
36. Plasminogen activators are involved in the degradation of bone by osteoclasts.
Everts V; Daci E; Tigchelaar-Gutter W; Hoeben KA; Torrekens S; Carmeliet G; Beertsen W
Bone; 2008 Nov; 43(5):915-20. PubMed ID: 18691680
[TBL] [Abstract][Full Text] [Related]
37. Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.
Vines DJ; Lee SW; Dichek DA; Ellis V
J Pept Sci; 2000 Sep; 6(9):432-9. PubMed ID: 11016879
[TBL] [Abstract][Full Text] [Related]
38. Urokinase plasminogen activator and TGF-beta production in immunosuppressed patients with and without P. Jiroveci infection.
Angelici E; Spezzano M; Vaccari S; Valentini SB; Romani R; Contini C; Canipari R
Microb Pathog; 2006 Jul; 41(1):1-9. PubMed ID: 16704917
[TBL] [Abstract][Full Text] [Related]
39. Angiostatic activity of synthetic inhibitors of urokinase type plasminogen activator.
Swiercz R; Skrzypczak-Jankun E; Merrell MM; Selman SH; Jankun J
Oncol Rep; 1999; 6(3):523-6. PubMed ID: 10203585
[TBL] [Abstract][Full Text] [Related]
40. Degradation of fibrin and elastin by intact human alveolar macrophages in vitro. Characterization of a plasminogen activator and its role in matrix degradation.
Chapman HA; Stone OL; Vavrin Z
J Clin Invest; 1984 Mar; 73(3):806-15. PubMed ID: 6368589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
